Results 281 to 290 of about 356,633 (356)

IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia. [PDF]

Blood Adv
Hui L, Xiao J, Zhao Z, Zhang J, Luan H, Zhang J, Sun Y, Meng X, Wang H, Li C, Li F, Ji S, Wei S, Li F, Yu H, Zheng C, Jiang Y, Wang Y, Li Z.   +18 more
europepmc   +1 more source

A Poly ( β ‐Amino Esters)‐Based Multicomponent Nanoparticle for Efficient mRNA Delivery to Acute Myeloid Leukemia Cells

Zheng Wang, Dehua Huang, Lanrong Wu, Yuheng Cao, Yejun Zhang, Chunyan Li, Jiang Jiang, Guangcun Chen, Qiangbin Wang   +8 more
openalex   +1 more source

Genocopy of EVI1‐AML with paraneoplastic diabetes insipidus: PRDM16 overexpression by t(1;2)(p36;p21) and enhancer hijacking

British Journal of Haematology, EarlyView.
Summary Diabetes insipidus (DI) in patients with acute myeloid leukaemia (AML) and chromosome 3q alterations (EVI1/PRDM3/MECOM overexpression) constitutes a poorly understood paraneoplasia. A 44‐year‐old patient presented with clinical and morphological features of this syndrome but, surprisingly, disclosed the rare translocation t(1;2)(p36;p21), with ...
Julian List, Etienne Sollier, Fiona Brown‐Burke, Katherine Kelly, Dietmar Pfeifer, Valeria Shlyakhto, Kristina Maas‐Bauer, Milena Pantic, Christoph Plass, Michael Lübbert   +9 more
wiley   +1 more source

Clonal Evolution of Pediatric Acute Myeloid Leukemia and Its Contribution to Disease Relapse

Umeda M, Kolekar P, Huskey AL, Suryaprakash S, Ma J, Li H, Westover T, Walsh MP, Song G, Liu Y, Tran Q, Balagopal V, Wang L, Brady SW, Gruber TA, Pounds S, Mead PE, Karol SE, Inaba H, Rubnitz JE, Ribeiro R, Ma X, Klco JM.   +22 more
europepmc   +1 more source

A Mutational Landscape in Acute Myeloid Leukemia: Overview and Prognostic Impacts. [PDF]

Diagnostics (Basel)
Chen J, Hassan F, Tirado CA.
europepmc   +1 more source

Mapping VEXAS‐associated and rare UBA1 variants in the United Kingdom: Insights from patient cohorts and the general population

British Journal of Haematology, EarlyView.
VEXAS syndrome is a late‐onset inflammatory disorder with rheumatological and haematological features. Epidemiological studies of VEXAS syndrome so far have been limited. Analysis of various UK cohorts estimates the incidence of VEXAS to be 1.51/100 000, or 171 new cases in the population of men over the age of 50 who are being investigated for myeloid
Ana Martinez Rodriguez, Leon Chang, Dorota Rowczenio, Alexandra Smith, Ebun Omoyinmi, James A. Poulter, Andrew McGregor, Sebastian Francis, Roochi Trikha, Adam Al‐Hakim, Kar Lok Kong, David G. Kent, Helen Lachmann, Austin Kulasekararaj, Catherine Cargo, Sinisa Savic   +15 more
wiley   +1 more source

<i>MECOM</i>-Rearranged Acute Myeloid Leukemia: Pathobiology and Management Strategies. [PDF]

Hematol Rep
Joshi U, Shallis RM.
europepmc   +1 more source

Comparability of external and internal control patients for the prospective randomized HOVON‐103 trial in older AML patients

British Journal of Haematology, EarlyView.
Summary Real‐world data (RWD) previously contributed to post‐marketing regulatory decision‐making, but are currently also considered as external controls to single‐arm trials. The use of RWD control data may be compromised by methodological issues, urging validation of RWD control cohorts.
Sjoerd J. F. Hermans, Jurjen Versluis, Erik D. van Werkhoven, Yvette van Norden, Jeroen J. W. M. Janssen, Gerwin A. Huls, Thomas Pabst, Dimitri A. Breems, Elizabeth Berkx, Avinash G. Dinmohamed, Peter C. Huijgens, Eric Sträng, Jesús María Hernández Rivas, Marta Sobas, Rosa Ayala Diaz, Joaquin Martinez Lopez, Klaus H. Metzeler, Torsten Haferlach, Christian Thiede, Carin A. Uyl‐de Groot, Lars Bullinger, Bob Löwenberg, Gert J. Ossenkoppele, Francesco Pignatti, Jan J. Cornelissen   +24 more
wiley   +1 more source

Current Therapeutic Strategies for FLT3-Mutated Acute Myeloid Leukemia: A Narrative Review. [PDF]

Cureus
Swanson L, Sharp J, Liaw A, Abi Abdallah D, Duriancik DM.   +4 more
europepmc   +1 more source

Impact of methotrexate‐dosing regimens for GVHD prophylaxis on clinical outcomes of HLA‐matched allogeneic HSCT

British Journal of Haematology, EarlyView.
Summary Severe graft‐versus‐host disease (GVHD) remains a major complication of allogeneic haematopoietic stem cell transplantation (allo‐HSCT), necessitating optimal immunosuppressive strategies. This retrospective study used data from the Japanese Transplant Registry Unified Management Program to compare three methotrexate (MTX)‐dosing regimens for ...
Tomotaka Suzuki, Tomoyasu Jo, Kota Yoshifuji, Tadakazu Kondo, Noriko Doki, Yoshinobu Kanda, Tetsuya Nishida, Yasushi Onishi, Noboru Asada, Takahiro Fukuda, Masashi Sawa, Yuta Hasegawa, Kentaro Serizawa, Shuichi Ota, Masatsugu Tanaka, Makoto Yoshimitsu, Yoshiko Atsuta, Junya Kanda   +17 more
wiley   +1 more source